Preclinical and clinical pharmacology of biotherapeutic agents: Saccharomyces boulardii.
about
Modulation of intestinal inflammation by yeasts and cell wall extracts: strain dependence and unexpected anti-inflammatory role of glucan fractionsOral spore-based probiotic supplementation was associated with reduced incidence of post-prandial dietary endotoxin, triglycerides, and disease risk biomarkers.Saccharomyces boulardii inhibits water and electrolytes changes induced by castor oil in the rat colon.
P2860
Preclinical and clinical pharmacology of biotherapeutic agents: Saccharomyces boulardii.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Preclinical and clinical pharmacology of biotherapeutic agents: Saccharomyces boulardii.
@ast
Preclinical and clinical pharmacology of biotherapeutic agents: Saccharomyces boulardii.
@en
Preclinical and clinical pharmacology of biotherapeutic agents: Saccharomyces boulardii.
@nl
type
label
Preclinical and clinical pharmacology of biotherapeutic agents: Saccharomyces boulardii.
@ast
Preclinical and clinical pharmacology of biotherapeutic agents: Saccharomyces boulardii.
@en
Preclinical and clinical pharmacology of biotherapeutic agents: Saccharomyces boulardii.
@nl
prefLabel
Preclinical and clinical pharmacology of biotherapeutic agents: Saccharomyces boulardii.
@ast
Preclinical and clinical pharmacology of biotherapeutic agents: Saccharomyces boulardii.
@en
Preclinical and clinical pharmacology of biotherapeutic agents: Saccharomyces boulardii.
@nl
P2860
P1476
Preclinical and clinical pharmacology of biotherapeutic agents: Saccharomyces boulardii.
@en
P2093
P2860
P304
P356
10.1179/JOC.2001.13.5.473
P577
2001-10-01T00:00:00Z